{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:23:41Z","timestamp":1757705021824,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10072-022-06379-z","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:02:36Z","timestamp":1662681756000},"page":"6909-6918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience"],"prefix":"10.1007","volume":"43","author":[{"given":"Mirjana","family":"Zdraljevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Jeremic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Lavrnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Basta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljiljana","family":"Hajdukovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejana R.","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3637-9935","authenticated-orcid":false,"given":"Ivana","family":"Berisavac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"issue":"10","key":"6379_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"6379_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","volume":"2","author":"JC Deenen","year":"2015","unstructured":"Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG (2015) The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis 2(1):73\u201385","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"6379_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000342777","volume":"40","author":"D Lavrnic","year":"2013","unstructured":"Lavrnic D, Basta I, Rakocevic-Stojanovic V, Stevic Z, Peric S, Nikolic A, Marjanovic I, Pekmezovic T (2013) Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979\u20132008. Neuroepidemiology 40(3):190\u2013194. https:\/\/doi.org\/10.1159\/000342777","journal-title":"Neuroepidemiology"},{"issue":"1","key":"6379_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"issue":"7","key":"6379_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S, M\u00e1rquez-Infante C, Pardo J, Coll-Cant\u00ed J, Jeric\u00f3 I, Illa I, Myasthenia NMD-ES Study Group (2015) Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 22(7):1056\u20131061. https:\/\/doi.org\/10.1111\/ene.12703","journal-title":"Eur J Neurol"},{"key":"6379_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11940-004-0034-3","volume":"6","author":"JF Kirmani","year":"2004","unstructured":"Kirmani JF, Yahia AM, Qureshi AI (2004) Myasthenic crisis. Curr Treat Options Neurol 6:3\u201315. https:\/\/doi.org\/10.1007\/s11940-004-0034-3","journal-title":"Curr Treat Options Neurol"},{"key":"6379_CR7","unstructured":"Ropper AH, Gress DR, Diringer MN, Green DM, Mayer SA, Bleck TP (2004) Treatment of the Critically Ill Patient With Myasthenia Gravis. Neurological and Neurosurgical Intensive Care. 4th ed. Lipincott Williams & Wilkins, Philadelphia, PA, pp 299\u2013311"},{"key":"6379_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM (2011) Myasthenic crisis. Neurohospitalist 1:16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"key":"6379_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548\u20131554. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a41211","journal-title":"Neurology"},{"key":"6379_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ene.12115","volume":"21","author":"J Spillane","year":"2014","unstructured":"Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS (2014) Myasthenia gravis: treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis. Eur J Neurol 21:171\u2013173. https:\/\/doi.org\/10.1111\/ene.12115","journal-title":"Eur J Neurol"},{"key":"6379_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-1331.1998.520137.x","volume":"5","author":"JI O\u2019Riordan","year":"1998","unstructured":"O\u2019Riordan JI, Miller DH, Mottershead JP, Hirsch NP, Howard RS (1998) The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 5:137\u2013142. https:\/\/doi.org\/10.1046\/j.1468-1331.1998.520137.x","journal-title":"Eur J Neurol"},{"key":"6379_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s10072-014-1659-y","volume":"35","author":"J Kalita","year":"2014","unstructured":"Kalita J, Kohat AK, Misra UK (2014) Predictors of outcome of myasthenic crisis. Neurol Sci 35:1109\u20131114. https:\/\/doi.org\/10.1007\/s10072-014-1659-y","journal-title":"Neurol Sci"},{"key":"6379_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1590\/s0004-282x2002000400001","volume":"60","author":"LC Werneck","year":"2002","unstructured":"Werneck LC, Scola RH, Germiniani FMB, Comerlato EA, Cunha FMB (2002) Myasthenic crisis: report of 24 cases. Arq Neuropsiquiatr 60:519\u2013524. https:\/\/doi.org\/10.1590\/s0004-282x2002000400001","journal-title":"Arq Neuropsiquiatr"},{"key":"6379_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00134-013-2960-6","volume":"39","author":"MS Damian","year":"2013","unstructured":"Damian MS, Ben-Shlomo Y, Howard R, Bellotti T, Harrison D, Griggs K, Rowan K (2013) The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barr\u00e9 syndrome admitted to critical care: an analysis of the Intensive Care National Audit & Research. Intens Care Med 39:1405\u20131412. https:\/\/doi.org\/10.1007\/s00134-013-2960-6","journal-title":"Intens Care Med"},{"issue":"3","key":"6379_CR15","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Sch\u00f6nenberger S, B\u00f6sel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR, German Myasthenic Crisis Study Group (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94(3):e299\u2013e313. https:\/\/doi.org\/10.1212\/WNL.0000000000008688","journal-title":"Neurology"},{"issue":"1","key":"6379_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12883-021-02412-4","volume":"21","author":"CW Hsu","year":"2021","unstructured":"Hsu CW, Chen NC, Huang WC, Lin HC, Tsai WC, Huang CC, Cheng BC, Tsai NW (2021) Hemogram parameters can predict in-hospital mortality of patients with myasthenic crisis. BMC Neurol 21(1):388. https:\/\/doi.org\/10.1186\/s12883-021-02412-4","journal-title":"BMC Neurol"},{"issue":"2","key":"6379_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/0972-2327.112466","volume":"16","author":"S Sharma","year":"2013","unstructured":"Sharma S, Lal V, Prabhakar S, Agarwal R (2013) Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study. Ann Indian Acad Neurol 16(2):203\u2013207. https:\/\/doi.org\/10.4103\/0972-2327.112466","journal-title":"Ann Indian Acad Neurol"},{"issue":"1","key":"6379_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-019-1384-5","volume":"19","author":"F Liu","year":"2019","unstructured":"Liu F, Wang Q, Chen X (2019) Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival. BMC Neurol 19(1):172. https:\/\/doi.org\/10.1186\/s12883-019-1384-5","journal-title":"BMC Neurol"},{"issue":"7","key":"6379_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archneur.65.7.929","volume":"65","author":"J Seneviratne","year":"2008","unstructured":"Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA (2008) Predictors of extubation failure in myasthenic crisis. Arch Neurol 65(7):929\u2013933. https:\/\/doi.org\/10.1001\/archneur.65.7.929","journal-title":"Arch Neurol"},{"key":"6379_CR20","unstructured":"Institute of Public Health of Serbia \u201cDr Milan Jovanovi\u0107 Batut\u201d, 2020, Report on infectious diseases in the Republic of Serbia for 2019, accessed 8 August 2022, https:\/\/www.batut.org.rs\/download\/izvestaji\/Godisnji%20izvestaj%20o%20zaraznim%20bolestima%202019.pdf"},{"issue":"4","key":"6379_CR21","first-page":"129","volume":"25","author":"YS Wong","year":"2016","unstructured":"Wong YS, Ong CT, Sung SF, Wu CS, Hsu YC, Su YH, Hung LC (2016) Clinical profile and outcome of myasthenic crisis in central Taiwan. Acta Neurol Taiwan 25(4):129\u2013135","journal-title":"Acta Neurol Taiwan"},{"issue":"1","key":"6379_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12028-008-9139-y","volume":"10","author":"JY Wu","year":"2009","unstructured":"Wu JY, Kuo PH, Fan PC, Wu HD, Shih FY, Yang PC (2009) The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care 10(1):35\u201342. https:\/\/doi.org\/10.1007\/s12028-008-9139-y","journal-title":"Neurocrit Care"},{"issue":"6","key":"6379_CR23","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0300060516669893","volume":"44","author":"Z Liu","year":"2016","unstructured":"Liu Z, Yao S, Zhou Q, Deng Z, Zou J, Feng H, Zhu H, Cheng C (2016) Predictors of extubation outcomes following myasthenic crisis. J Int Med Res 44(6):1524\u20131533. https:\/\/doi.org\/10.1177\/0300060516669893","journal-title":"J Int Med Res"},{"issue":"9A","key":"6379_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1590\/0004-282X20130108","volume":"71","author":"DA Godoy","year":"2013","unstructured":"Godoy DA, Mello LJ, Masotti L, Di Napoli M (2013) The myasthenic patient in crisis: an update of the management in neurointensive care unit. Arq Neuropsiquiatr 71(9A):627\u2013639. https:\/\/doi.org\/10.1590\/0004-282X20130108","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"6379_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/0028-3886","volume":"53","author":"JM Murthy","year":"2005","unstructured":"Murthy JM, Meena AK, Chowdary GV, Naryanan JT (2005) Myasthenic crisis: clinical features, complications and mortality. Neurol India 53(1):37\u201340. https:\/\/doi.org\/10.4103\/0028-3886","journal-title":"Neurol India"},{"issue":"23","key":"6379_CR26","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505","journal-title":"Neurology"},{"key":"6379_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","volume":"11","author":"C Rodolico","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A, Vita G (2020) MuSK-associated myasthenia gravis: clinical features and management. Front Neurol 11:660. https:\/\/doi.org\/10.3389\/fneur.2020.00660","journal-title":"Front Neurol"},{"issue":"12","key":"6379_CR28","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","volume":"268","author":"N K\u00f6nig","year":"2021","unstructured":"K\u00f6nig N, Stetefeld HR, Dohmen C, Mergenthaler P, Kohler S, Sch\u00f6nenberger S, B\u00f6sel J, Lee DH, Gerner ST, Huttner HB, Schneider H, Reichmann H, Fuhrer H, Berger B, Zinke J, Alberty A, Kleiter I, Schneider-Gold C, Roth C, Dunkel J, Steinbrecher A, Thieme A, Schlachetzki F, Linker RA, Angstwurm K, Meisel A, Neumann B, German Myasthenic Crisis Study Group (2021) MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol 268(12):4824\u20134833. https:\/\/doi.org\/10.1007\/s00415-021-10603-9","journal-title":"J Neurol"},{"issue":"7","key":"6379_CR29","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","volume":"10","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K (2021) Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med 10(7):1537. https:\/\/doi.org\/10.3390\/jcm10071537","journal-title":"J Clin Med"},{"issue":"6","key":"6379_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60(6):693\u2013699. https:\/\/doi.org\/10.1002\/mus.26689","journal-title":"Muscle Nerve"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06379-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:16:35Z","timestamp":1668446195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06379-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6379"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06379-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report following conflicts of interest, all outside this work. Stojan Peric has received lecture honoraria from Pfizer, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc and Salveo; research grants from Kedrion, Octapharma and Argenx; consultant fees from argenx, Mylan and Roche; and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc and Berlin Chemie Menarini. Dragana Lavrnic has received lecture honoraria from Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc and Salveo; research grants from Octapharma and travel grants from Octapharma, Teva Actavis, Sanofi Genzyme, Adoc and Berlin Chemie Menarini. Ivana Basta has received lecture honoraria from Pfizer, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag; research grants from Kedrion, Octapharma and Argenx; and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc and Berlin Chemie Menarini. Dejana R. Jovanovic has received speaker honoraria from Boehringer-Ingelheim, Bayer, Sanofi,\u00a0Pfizer and Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethical board of the Neurology Clinic, University Clinical Center of Serbia. Patient consent was not required since patients\u2019 data were anonymized and only retrospective data were obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}